Literature DB >> 9833739

Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.

S Louisirirotchanakul1, S Beddows, R Cheingsong-Popov, N Shaffer, T D Mastro, P Auewarakul, S Likanonsakul, C Wasi, J Weber.   

Abstract

The range and specificity of the humoral immune response to HIV-1 subtypes B and E was investigated in Thai samples. Sera from HIV-1-positive subjects, consisting of subtypes B (n = 24) and E (n = 138), were characterized in relation to the neutralization of primary isolates and T-cell line-adapted (TCLA) strains and binding to monomeric gp120, the CD4/gp120 binding site (BS), and V3 peptides. A subtype-specific pattern of antibody binding was observed with the exception of the CD4/gp 120MN BS. Neutralization of TCLA strains (n = 4) was strongly type-specific (p = .002); however, neutralization of primary isolates (n = 8) was weak and group specific. Thus, the subtype specificity of B and E sera in the neutralization of TCLA strains, but not primary isolates, supports the dominance of the V3 region in TCLA virus neutralization but does not support the distinction of subtypes B and E as discrete neutralization serotypes in Thailand.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Antibodies; Asia; Biology; Clinical Research; Developing Countries; Diseases; Hiv Infections; Immunity; Immunologic Factors; Physiology; Research Methodology; Research Report; Southeastern Asia; Thailand; Viral Diseases

Mesh:

Substances:

Year:  1998        PMID: 9833739     DOI: 10.1097/00042560-199812010-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  5 in total

Review 1.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.

Authors:  Raiees Andrabi; M A Makhdoomi; Rajesh Kumar; Manju Bala; Hilal Parray; Arjun Gupta; Ankita Kotnala; Velpandian Thirumurthy; Kalpana Luthra
Journal:  J Clin Immunol       Date:  2014-03-29       Impact factor: 8.317

3.  Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Authors:  James M Binley; Terri Wrin; Bette Korber; Michael B Zwick; Meng Wang; Colombe Chappey; Gabriela Stiegler; Renate Kunert; Susan Zolla-Pazner; Hermann Katinger; Christos J Petropoulos; Dennis R Burton
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus.

Authors:  Luzia M Mayr; Rebecca L Powell; Johnson N Ngai; William A Takang; Arthur Nádas; Phillipe N Nyambi
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

5.  Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India.

Authors:  Raiees Andrabi; Manju Bala; Rajesh Kumar; Naveet Wig; Anjali Hazarika; Kalpana Luthra
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.